This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y
by Zacks Equity Research
IT posts strong second-quarter 2025 with EPS up 18.5% and revenues rising 5.6% y/y, but trims its full-year revenue and EBITDA guidance.
Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y
by Zacks Equity Research
VRSK posts 8.1% y/y EPS growth in second-quarter 2025, and lifts its revenue and EBITDA guidance despite a lowered EPS outlook.
WM Earnings & Revenues Beat Estimates in Q2, Increase Y/Y
by Zacks Equity Research
WM reports 19% y/y revenue growth and a 5.5% EPS rise in second-quarter 2025 despite lowering the yearly revenue guidance.
Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss
by Zacks Equity Research
FI tops second-quarter 2024 earnings estimates on strong margins and segment growth. However, its shares drop 15.7% on the revenue miss.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA (IQV) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
by Harshit Gupta
VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.
Fiserv's Q2 Earnings Surpass Estimates, Revenues Increase Y/Y
by Zacks Equity Research
FI posts solid second-quarter 2025 earnings growth, which has boosted full-year EPS outlook, but revenue miss keeps the stock trailing its peers.
Stock Market News for Jul 23, 2025
by Zacks Equity Research
Wall Street closed mixed on Tuesday as market participants were busy weighing uncertainties related to tariff rates and trade policies.
IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y
by Zacks Equity Research
IQV tops second-quarter 2025 estimates, with earnings up 6.4% and revenue rising 5.5%. It cuts the 2025 EBITDA guidance.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of +1.81% and +1.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to IQVIA (IQV) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of IQVIA (IQV) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
IQV is set to report Q2 results on July 22, with both earnings and revenues expected to rise on strong demand across segments.
Top Stock Reports for Amazon.com, Meta Platforms & Shopify
by Mark Vickery
AMZN, META, and SHOP gain ground as AI, new tools, and global growth strategies fuel momentum despite tariff headwinds.
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva Expands Market Reach Through Targeted Strategic Partnerships
by Harshit Gupta
VEEV gains momentum in 2025 with strategic partnerships fueling growth in AI, clinical research, and compliance.
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
by Harshit Gupta
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
by Harshit Gupta
Veeva's new AI layer in Vault boosts automation and deepens pharma reliance, sharpening its edge in life sciences tech.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
by Indrajit Bandyopadhyay
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.